NAD+, NMN, or NR: Which Molecule Does Your Body Actually Need?

Is NMN better than NAD+ injections? No, because NMN is a precursor, meaning it is a raw ingredient your body converts into NAD+. NAD+ injections deliver the active molecule directly into the body, bypassing some conversion steps [1]. While NMN and NR (Nicotinamide Riboside) are popular, they rely on your body's declining ability to manufacture the final product.

• NAD+ is the goal: This is the final product your cells actually use.

• NMN & NR are precursors: They are raw ingredients that become NAD+.

• Conversion efficiency may decline with age: As you age, your body gets worse at converting ingredients (Biosynthesis).

• Injections cheat the system: They deliver the finished NAD+ molecule, skipping the need for some conversion.

The easiest way to understand the difference is to think about baking a cake.

NAD+ is the cake. It is the finished product that you can eat and enjoy immediately.

NMN and NR are the flour and eggs. They are the ingredients.

When you take an NMN pill, you are handing your body a bag of flour and asking it to make something.

If your cells are young, healthy and efficient, that works fine. But as we age, cellular efficiency may decline, which can reduce the conversion of precursors into NAD+.

Your body has a specific process for making NAD+. It is called the Salvage Pathway.

Think of this as an assembly line:

1. You eat food containing Vitamin B3 or take supplements like NR.

2. Your body converts NR into NMN.

3. Your body then converts NMN into the final NAD+ molecule.

This process is called biosynthesis.

When you are 20, this process is fast. When you are 50, it slows down. The enzymes responsible for this molecular conversion become scarce and less efficient with age [2].

This is why increasing NMN intake may not always lead to proportional increases in NAD+.

NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) are chemically similar to NAD+, but they are not the same thing.

They are precursors. They are waiting to be changed.

• NR: The smallest molecule. It enters cells easily but requires two steps to become NAD+ [2].

• NMN: One step closer. It only requires one step to become NAD+.

However, both still rely on your body's internal machinery. If your internal enzymes are sluggish due to ageing, increasing precursor intake may not always lead to proportional increases in NAD+.

Vivere provides the final NAD+ molecule directly via subcutaneous injection.

We do not ask your body to do much work.

• No Digestion: It skips the stomach acid.

• No Conversion: May bypass some steps in the NAD+ salvage pathway

• More Immediate Systemic Availability: The molecule enters your body ready to be used by your cells.

This increases the likelihood that circulating NAD+ is available systemically.  You are not hoping for a chemical reaction; you are supplying the result.

If you are feeling the effects of ageing, brain fog, fatigue, or slow recovery, that can be completely normal, NAD+ metabolism may be less efficient in some individuals.

Rather than relying solely on your body to perform all biosynthesis, targeted support may help. Targeted NAD+ support may help support cellular energy production.

“While precursors like NMN and NR show promise in animal studies, some aspects of human NAD⁺ biosynthesis may change with age. Relying on a precursor requires your body to enzymatically convert it, a process that may be less efficient in certain individuals. Administering NAD⁺ may help increase the availability of NAD⁺-related metabolites.”

"As research into NAD+ continues to evolve, it is important to recognise that there is no single ‘best’ approach for everyone. Whether using precursors like NMN and NR or exploring direct NAD+ therapies, outcomes depend on how your body absorbs, converts and utilises these compounds. Focusing on overall metabolic health through nutrition, sleep and lifestyle remains fundamental, with supplementation acting as a complementary tool rather than a standalone solution."

[1] A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+

[2] NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells | Nature Communications